Therefore, the introduction of RDW is a good complement to the deficiency of the pneumonia severity assessment scale and is obtained quickly without additional cost, which is different from PCT, copeptin, atrial natriuretic peptide, and other biomarkers. The gene discussed is AVP; the disease is susceptibility to pneumonia measurement.